Elasmogen is using a combination of in-house development and strategic partnerships to accelerate an expanding pipeline of new and differentiated drug products towards clinical studies.

In-house

Auto-immune mediated anti-inflammatory programmes ELN/21 and ELN/22

Strategic Partnerships

soloMER Drug Conjugate (SDC) programme with Almac Discovery Ltd (ELN/ 11) and a Bio-processing programme with Merck Inc (ELN/ 31).

Pipeline